Novartis has settled a lawsuit alleging it profited from Henrietta Lacks' cells, taken without consent in 1951. The agreement, finalized in Maryland federal court, follows a similar 2023 settlement with Thermo Fisher Scientific.
U.S. President Donald Trump's plan to cap drug prices could slow pharmaceutical innovation, delay Canadians' access to new treatments, and potentially raise prices in Canada, warns an expert.
Alberta Health Services has destroyed half of its imported Turkish-made children's pain medication due to expiration dates, totaling 700,000 bottles that couldn't be donated internationally.
Novo Nordisk has filed a lawsuit against Hims & Hers Health alleging patent infringement on semaglutide, escalating tensions between the companies after their partnership dissolved last year.
Health Canada has issued a Canada-wide recall for MAR-Amlodipine 5 mg tablets after discovering some bottles contain the wrong drug, posing serious health risks including dangerously high blood pressure and organ damage.
Health Canada has announced a recall for specific lots of Midodrine and MAR-Amlodipine tablets used to treat low and high blood pressure. Patients are urged to verify their prescriptions immediately.
Health Canada has announced a recall for specific blood pressure medications due to a packaging error that led to pill mix-ups between two different drugs.
Novo Nordisk shares experience a significant surge following news that Hims & Hers has withdrawn its $49 weight loss pill from the U.S. market due to FDA pressure, impacting competitive dynamics.
Shares of pharmaceutical giant Novo Nordisk have rebounded following a U.S. FDA announcement targeting illegal copies of its drugs, amid broader market and regulatory developments.
Novo Nordisk threatens legal action against Hims & Hers for launching a generic version of its weight-loss drug Wegovy, escalating tensions in the pharmaceutical industry.
Eli Lilly and Novo Nordisk present contrasting financial forecasts for their weight loss drugs, revealing strategic differences in patent life, marketing, and market positioning.
Novo Nordisk announces the launch of its oral semaglutide medication, branded as Ozempic pill, for diabetes treatment starting in the second quarter of 2026.
Eli Lilly reports strong quarterly earnings, exceeding analyst forecasts, and issues an optimistic outlook driven by unprecedented demand for its weight-loss medications.
New clinical data from Pfizer's weight-loss drug candidate has raised significant questions about potential side effects, leading to a notable drop in the company's share price.
Novo Nordisk's new Wegovy weight-loss pill recorded 18,410 prescriptions in its first full week post-launch, signaling robust early demand in the pharmaceutical market.
Health Canada alerts the public about dangerous counterfeit versions of diabetes and weight-loss medications Ozempic and Mounjaro circulating in the market.
Calgary's Psygen Labs, a federally licensed facility, manufactures pharmaceutical-grade psychedelics like psilocybin and MDMA for global research, aiming to address mental health and addiction.
The patent for semaglutide (Ozempic) has expired in Canada, paving the way for affordable generic versions. This could dramatically increase access to weight-loss and diabetes medications.
TekniPlex Healthcare will showcase expanded multidose vial production and advanced barrier materials at Pharmapack 2026 in Paris, highlighting innovations for ophthalmic and sterile applications.
Stablepharma and AFT Pharmaceuticals partner to develop fridge-free injectables for anti-infective and oncology markets. Read about this innovation set to transform global medicine access.
A Calgary doctor predicts generic versions of Ozempic and Wegovy could reduce costs by up to a third. Learn about the patent expiry and five companies seeking approval to manufacture cheaper alternatives in Canada.
A pharmacist in northwest Edmonton has been suspended and fined for professional misconduct. Get the details on the sanctions from the Alberta College of Pharmacists.
Health Canada reviews nine generic semaglutide submissions. Cheaper versions of Ozempic and Wegovy could soon improve access for diabetes and weight loss patients in British Columbia.
Danish pharmaceutical giant Novo Nordisk signals upcoming challenges in international markets. Get the latest business insights and analysis on this developing story.
Semaglutide, sold as Ozempic, is now off-patent in Canada. This move could slash costs by up to 75%, dramatically increasing access to the popular diabetes and weight-loss drug for Canadians.
Citeline and Risklick partner to transform clinical trial design with AI, aiming to reduce costly amendments and accelerate drug development timelines for Canadian researchers.
The CEO of Novo Nordisk disclosed that an estimated 1.5 million Americans are using compounded versions of GLP-1 drugs. Learn about the market implications and safety concerns.
Novo Nordisk's CEO says its new obesity pill will tap into millions not using GLP-1s due to needle fears. The drugmaker battles Eli Lilly and compounders in a massive market.
Health Canada issues a public warning about counterfeit Viagra and Cialis tablets found at a Mississauga distributor. Learn how to identify fake medications and protect your health.
A newly approved Alzheimer's drug has been administered for the first time in Canada, providing fresh hope to patients. However, significant questions about coverage costs remain unresolved.